OBJECTIVE: To quantify the relative contribution of elevated 2-hr glucose, fasting glucose (FPG), and HbA1c to all-cause mortality. STUDY DESIGN AND SETTING: A joint analysis of two prospective studies with baseline glycemia measurements. RESULTS: The multivariate adjusted hazard ratios (HRs) corresponding to a one standard deviation increase in HbA1c were 1.14 (95% CI 1.03-1.25), 1.08 (0.98-1.19) for FPG and 1.15 (1.05-1.27) for 2-hr glucose, respectively. Entering the 2-hr glucose to the model based on the FPG and HbA1c significantly improved the prediction of mortality, whereas neither FPG, nor HbA1c added significant information once 2-hr glucose was in the models. In subjects with FPG <7.0 mmol/L and HbA1c < or = 6.5%, the HR was 1.35 (1.03-1.78) in men with 2-hr glucose > or = 7.8 mmol/L compared with men with 2-hr glucose <7.8 mmol/L. CONCLUSION: Elevated 2-hr glucose was a predictor of mortality independent of the levels of fasting glucose and HbA1c.
OBJECTIVE: To quantify the relative contribution of elevated 2-hr glucose, fasting glucose (FPG), and HbA1c to all-cause mortality. STUDY DESIGN AND SETTING: A joint analysis of two prospective studies with baseline glycemia measurements. RESULTS: The multivariate adjusted hazard ratios (HRs) corresponding to a one standard deviation increase in HbA1c were 1.14 (95% CI 1.03-1.25), 1.08 (0.98-1.19) for FPG and 1.15 (1.05-1.27) for 2-hr glucose, respectively. Entering the 2-hr glucose to the model based on the FPG and HbA1c significantly improved the prediction of mortality, whereas neither FPG, nor HbA1c added significant information once 2-hr glucose was in the models. In subjects with FPG <7.0 mmol/L and HbA1c < or = 6.5%, the HR was 1.35 (1.03-1.78) in men with 2-hr glucose > or = 7.8 mmol/L compared with men with 2-hr glucose <7.8 mmol/L. CONCLUSION: Elevated 2-hr glucose was a predictor of mortality independent of the levels of fasting glucose and HbA1c.
Authors: April P Carson; Caroline S Fox; Darren K McGuire; Emily B Levitan; Martin Laclaustra; Devin M Mann; Paul Muntner Journal: Circ Cardiovasc Qual Outcomes Date: 2010-10-05
Authors: Carlos Lorenzo; Sara Hartnett; Anthony J Hanley; Marian J Rewers; Lynne E Wagenknecht; Andrew J Karter; Steven M Haffner Journal: J Clin Endocrinol Metab Date: 2013-02-28 Impact factor: 5.958
Authors: Carlos Lorenzo; Lynne E Wagenknecht; Anthony J G Hanley; Marian J Rewers; Andrew J Karter; Steven M Haffner Journal: Diabetes Care Date: 2010-06-23 Impact factor: 19.112
Authors: Beth E Cohen; Elizabeth Barrett-Connor; Christina L Wassel; Alka M Kanaya Journal: Diabetes Res Clin Pract Date: 2009-08-09 Impact factor: 5.602
Authors: E B Levitan; S Liu; M J Stampfer; N R Cook; K M Rexrode; P M Ridker; J E Buring; J E Manson Journal: Diabetologia Date: 2007-11-28 Impact factor: 10.122